PBIO Pressure Biosciences
We are a leader in the development and sale of innovative, broadly enabling, pressure-based platform solutions for the worldwide life sciences industry. Our solutions are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus has been in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology platform) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be acceptably preserved using existing non-thermal technologies.
Company profile
Ticker
PBIO
Exchange
Website
CEO
Richard T. Schumacher
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
BOSTON BIOMEDICA INC
SEC CIK
Corporate docs
IRS number
42652826
PBIO stock data
()
Press releases
Pressure BioSciences Discusses Partnerships with Leica Microsystems (Cancer Diagnostics) and Ohio State University (Food Industry Consortium) with The Stock Day Podcast
15 Mar 21
Transformative Impact for Food Industry Consortium Formed by Pressure BioSciences and The Ohio State University Discussed in Showcase Video from Emerging Technology Insider
4 Mar 21
How Nanoemulsion Technology Is Drastically Affecting the Food & Beverage Industry
24 Feb 21
Pressure BioSciences and The Ohio State University Announce Food Industry Consortium to Advance Commercialization of PBI's Ultra Shear Technology
24 Feb 21
Pressure BioSciences and The Ohio State University Announce Food Industry Consortium to Advance Commercialization of PBI's Ultra Shear Technology
24 Feb 21
Investment data
Securities sold
Number of investors
Calendar
1 Apr 21
13 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 94.75K | 94.75K | 94.75K | 94.75K | 94.75K | 94.75K |
| Cash burn (monthly) | (positive/no burn) | 1.93K | 272.92K | 384.46K | 368.76K | 468.83K |
| Cash used (since last report) | n/a | 12.53K | 1.77M | 2.49M | 2.39M | 3.04M |
| Cash remaining | n/a | 82.22K | -1.68M | -2.4M | -2.3M | -2.95M |
| Runway (months of cash) | n/a | 42.6 | -6.1 | -6.2 | -6.2 | -6.3 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 10 Dec 20 | Peterson Jeffrey N | COMMON STOCK | Other | Aquire J | No | No | 1.55 | 1,241 | 1.92K | 21,714 |
| 10 Dec 20 | Schumacher Richard T | Common Stock | Other | Aquire J | No | No | 1.55 | 284 | 440.2 | 37,320 |
| 10 Dec 20 | Pollack Kevin | Common Stock | Other | Aquire J | No | No | 1.55 | 662 | 1.03K | 20,905 |
| 10 Dec 20 | Mangiardi Vito J | COMMON STOCK | Other | Aquire J | No | No | 1.55 | 142 | 220.1 | 12,695 |
| 10 Dec 20 | Urdea Michael S | Common Stock | Other | Aquire J | No | No | 1.55 | 653 | 1.01K | 17,506 |
Institutional ownership Q4 2019
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
0.0% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 1 |
| Opened positions | 1 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 1K |
| Total shares | 404 |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|---|---|
| Victory Capital Management | 404 | $1K |
Financial report summary
?Competition
HubManagement Discussion
- We had total revenue of $1,809,993, in the year ended December 31, 2019 as compared with $2,457,871 in the prior year, a 26% decrease. The decrease was due to a decrease in product sales and grant revenue.
- Products, Services, and Other. Revenue from the sale of products and services was $1,809,993 in the year ended December 31, 2019 compared with $2,200,539 in the year ended December 31, 2018, an 18% decrease. Revenue included sales of both PBI and CS’s pressure-based products and sales of our new Barofold Contract Services. Sales of instrumentation decreased in 2019 by $765,101 or 54%, from $1,418,731 in 2018 to $653,630 in 2019. Sales of consumables were $298,385 for the year ended December 31, 2019 compared to $235,132 for the same period in 2018, an increase of $63,253 or 27%. Sales of Barofold Contract Services increased from $118,383 in 2018 to $380,800 in 2019. Products, Services, and Other Revenue included $59,456 from non-cash transactions in the current year while the prior year included non-cash transactions of $91,265. Revenue from non-cash transactions was recognized based on the carrying value of the assets involved per ASC 845.
- Grant Revenue. During 2019, we recorded $0 of grant revenue as compared with $257,332 in 2018. In December 2014, the Company was awarded a $1,020,969 SBIR Phase II grant (2R44HG007136) from the National Human Genome Research Institute of the NIH, which expired in 2018.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
CWX, device, Hedging, lesser, MicroPestle, prohibited, Similarly, week
Removed:
Arrangement, guaranteeing, imputed, personally, Registrant
Financial reports
NT 10-K
Notice of late annual filing
1 Apr 21
10-Q
2020 Q3
Quarterly report
16 Nov 20
10-Q
2020 Q2
Quarterly report
14 Aug 20
10-Q
2020 Q1
Quarterly report
29 Jun 20
10-K
2019 FY
Annual report
14 Apr 20
NT 10-K
Notice of late annual filing
31 Mar 20
10-Q
2019 Q3
Quarterly report
13 Dec 19
NT 10-Q
Notice of late quarterly filing
14 Nov 19
10-Q
2019 Q2
Quarterly report
15 Aug 19
NT 10-Q
Notice of late quarterly filing
15 Aug 19
Current reports
8-K
Entry into a Material Definitive Agreement
31 Dec 20
8-K
Submission of Matters to a Vote of Security Holders
9 Dec 20
8-K
Entry into a Material Definitive Agreement
6 Nov 20
8-K
Entry into a Material Definitive Agreement
9 Oct 20
8-K
Entry into a Material Definitive Agreement
8 Jul 20
8-K
Other Events
15 May 20
8-K
Entry into a Material Definitive Agreement
6 Mar 20
8-K
Entry into a Material Definitive Agreement
5 Feb 20
8-K
Entry into a Material Definitive Agreement
27 Dec 19
8-K
Pressure BioSciences Prepares for Growth, Adding Daniel J. Shea as Chief Financial Officer
20 Sep 19
Registration and prospectus
D
Indefinite amount in equity / options / securities to be acquired, sold $17.46M, 43 investors
20 Mar 19
RW
Registration withdrawal request
14 Aug 17
8-A12B
Registration of securities on exchange
9 Aug 17
S-1/A
IPO registration (amended)
9 Aug 17
S-1/A
IPO registration (amended)
28 Jun 17
S-1/A
IPO registration (amended)
27 Jun 17
S-1/A
IPO registration (amended)
15 Jun 17
S-1/A
IPO registration (amended)
10 Apr 17
S-1
IPO registration
21 Dec 16
D
$6.25M in equity / options / securities to be acquired, sold $5.01M, 22 investors
26 Jan 16
Proxies
DEF 14A
Definitive proxy
30 Oct 20
DEF 14A
Definitive proxy
6 Nov 19
DEFA14A
Additional proxy soliciting materials
22 Oct 18
DEF 14A
Definitive proxy
22 Oct 18
DEF 14A
Definitive proxy
16 Nov 17
DEF 14A
Definitive proxy
14 Nov 16
PRE 14A
Preliminary proxy
31 Oct 16
DEF 14A
Definitive proxy
19 Nov 15
PRE 14A
Preliminary proxy
8 Nov 15
DEF 14A
Definitive proxy
18 Nov 14
Other
EFFECT
Notice of effectiveness
25 Sep 11
UPLOAD
Letter from SEC
21 Dec 09
CORRESP
Correspondence with SEC
2 Dec 09
UPLOAD
Letter from SEC
1 Dec 09
CORRESP
Correspondence with SEC
16 Nov 09
UPLOAD
Letter from SEC
4 Nov 09
UPLOAD
Letter from SEC
21 Aug 08
CORRESP
Correspondence with SEC
20 Aug 08
CORRESP
Correspondence with SEC
20 Aug 08
UPLOAD
Letter from SEC
19 Aug 08
Ownership
SC 13G
PRESSURE BIOSCIENCES / LG CAPITAL FUNDING ownership change
15 Mar 21
4
PRESSURE BIOSCIENCES / Michael S Urdea ownership change
11 Dec 20
4
PRESSURE BIOSCIENCES / Vito J Mangiardi ownership change
11 Dec 20
4
PRESSURE BIOSCIENCES / Kevin Pollack ownership change
11 Dec 20
4
PRESSURE BIOSCIENCES / RICHARD T SCHUMACHER ownership change
11 Dec 20
4
PRESSURE BIOSCIENCES / JEFFREY N PETERSON ownership change
11 Dec 20
4
PRESSURE BIOSCIENCES / Michael S Urdea ownership change
31 Aug 20
4
PRESSURE BIOSCIENCES / RICHARD T SCHUMACHER ownership change
31 Aug 20
4
PRESSURE BIOSCIENCES / Kevin Pollack ownership change
31 Aug 20
4
PRESSURE BIOSCIENCES / JEFFREY N PETERSON ownership change
31 Aug 20
Patents
GRANT
Utility
System for high pressure, high shear processing of fluids
2 Nov 20
A method for high fluid shear processing of a fluid uses an isolator that has a first sub-chamber for containing a first fluid and a second sub-chamber for containing a second fluid defined by a separator positioned in the chamber and movable between a first end of the chamber and a second end of the chamber.
GRANT
Utility
Sample preparation devices and methods
13 Jul 20
Devices and methods for sample preparation via pressure cycling technology are disclosed.